Skip to main content
Erschienen in: American Journal of Cardiovascular Drugs 6/2023

06.10.2023 | Original Research Article

Colchicine for the Prevention of Recurrent Arrhythmia After Catheter Ablation of Atrial Fibrillation: Results of a Single-Center, Retrospective Study

verfasst von: Kristen Bova Campbell, Stephanie Dougherty Eickman, Tracy Truong, Eric Black-Maier, Adam S. Barnett, Allen Wang, Cynthia L. Green, James P. Daubert, Robert K. Lewis, Brett D. Atwater, Sana M. Al-Khatib, Tristram D. Bahnson, Kevin L. Thomas, Kevin P. Jackson, Larry R. Jackson, Sean Pokorney, Camille Frazier-Mills, Jonathan P. Piccini

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

There is evidence to suggest that colchicine reduces the risk of recurrent atrial fibrillation (AF) after catheter ablation; however, the tolerability and safety of colchicine in routine practice is unknown.

Methods

Patients undergoing catheter ablation for AF who received colchicine after ablation were matched 1:1 to patients who did not by age, sex, and renal function. Recurrent AF was compared between groups categorically at 12 months and via propensity weighted Cox proportional hazards models with and without a 3-month blanking period.

Results

Overall, 180 patients (n = 90 colchicine and n = 90 matched controls) were followed for a median (Q1, Q3) of 10.3 (7.0, 12.0) months. Mean age was 65.3 ± 9.1 years, 33.9% were women, mean CHA2DS2-VASc score was 2.9 ± 1.5, and 51.1% had persistent AF. Most patients (70%) received colchicine 0.6 mg daily for a median of 30 days. In the colchicine group, 55 patients (61.1%) were receiving at least one known interacting medication with colchicine. After ablation, one patient required colchicine dose reduction and four patients required discontinuation. After adjusting for covariate imbalance using propensity weighting, no significant association between colchicine use and AF recurrence was identified (adjusted hazard ratio 0.94, 95% confidence interval [CI] 0.48–1.85; p = 0.853). No significant association was found between colchicine use and all-cause hospitalizations (adjusted odds ratio 0.74, 95% CI 0.28–1.96; p = 0.548).

Conclusion

Despite the frequent presence of drug–drug interactions, a 30-day course of colchicine is well-tolerated after AF ablation; however, we did not observe any association between colchicine and lower rates of AF recurrence or hospitalization.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33(5):369–409.CrossRefPubMedPubMedCentral Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Arrhythm. 2017;33(5):369–409.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2(4):349–61.CrossRefPubMed Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009;2(4):349–61.CrossRefPubMed
3.
Zurück zum Zitat Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24):2498–505.CrossRefPubMed Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24):2498–505.CrossRefPubMed
4.
Zurück zum Zitat Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57(2):160–6.CrossRefPubMed Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol. 2011;57(2):160–6.CrossRefPubMed
5.
Zurück zum Zitat Bunch TJ, May HT, Bair TL, et al. The impact of age on 5-year outcomes after atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol. 2016;27(2):141–6.CrossRefPubMed Bunch TJ, May HT, Bair TL, et al. The impact of age on 5-year outcomes after atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol. 2016;27(2):141–6.CrossRefPubMed
6.
Zurück zum Zitat Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):237–42.CrossRefPubMed Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(3):237–42.CrossRefPubMed
7.
Zurück zum Zitat Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122(23):2368–77.CrossRefPubMed Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122(23):2368–77.CrossRefPubMed
8.
Zurück zum Zitat De Pooter J, Strisciuglio T, El Haddad M, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure. JACC Clin Electrophysiol. 2019;5(3):295–305.CrossRefPubMed De Pooter J, Strisciuglio T, El Haddad M, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure. JACC Clin Electrophysiol. 2019;5(3):295–305.CrossRefPubMed
9.
Zurück zum Zitat Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol. 2010;56(18):1463–72.CrossRefPubMed Koyama T, Tada H, Sekiguchi Y, et al. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol. 2010;56(18):1463–72.CrossRefPubMed
10.
Zurück zum Zitat Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21):2021–8.CrossRefPubMed Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21):2021–8.CrossRefPubMed
11.
Zurück zum Zitat Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol. 2009;103(9):1249–54.CrossRefPubMed Koyama T, Sekiguchi Y, Tada H, et al. Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation. Am J Cardiol. 2009;103(9):1249–54.CrossRefPubMed
12.
Zurück zum Zitat Balouch MA, Kolek MJ, Darbar D. Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob Cardiol Sci Pract. 2014;2014(1):24–36.PubMedPubMedCentral Balouch MA, Kolek MJ, Darbar D. Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways. Glob Cardiol Sci Pract. 2014;2014(1):24–36.PubMedPubMedCentral
13.
Zurück zum Zitat Deftereos S, Giannopoulos G, Efremidis M, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11(4):620–8.CrossRefPubMed Deftereos S, Giannopoulos G, Efremidis M, et al. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm. 2014;11(4):620–8.CrossRefPubMed
14.
Zurück zum Zitat Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817–25.CrossRefPubMed Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817–25.CrossRefPubMed
15.
Zurück zum Zitat Dixon DL, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug-drug interactions with colchicine and cardiovascular medications: a review. Am Heart J. 2022;252:42–50.CrossRefPubMed Dixon DL, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug-drug interactions with colchicine and cardiovascular medications: a review. Am Heart J. 2022;252:42–50.CrossRefPubMed
16.
Zurück zum Zitat Colcrys (colchicine) package insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2020. Colcrys (colchicine) package insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2020.
17.
Zurück zum Zitat Black-Maier E, Steinberg BA, Trulock KM, et al. Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. J Arrhythm. 2020;36(1):84–92.CrossRefPubMedPubMedCentral Black-Maier E, Steinberg BA, Trulock KM, et al. Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. J Arrhythm. 2020;36(1):84–92.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Black-Maier E, Ren X, Steinberg BA, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2018;15(5):651–7.CrossRefPubMed Black-Maier E, Ren X, Steinberg BA, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2018;15(5):651–7.CrossRefPubMed
19.
Zurück zum Zitat Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178(2):641–6.CrossRefPubMed Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a potential mediator of cardiac fibrosis associated with inflammation. J Immunol. 2007;178(2):641–6.CrossRefPubMed
20.
Zurück zum Zitat Casanova P, Artola RT, Mihos CG, Pineda AM, Santana O. The cardiovascular effects of colchicine: a comprehensive review. Cardiol Rev. 2015;23(6):317–22.CrossRefPubMed Casanova P, Artola RT, Mihos CG, Pineda AM, Santana O. The cardiovascular effects of colchicine: a comprehensive review. Cardiol Rev. 2015;23(6):317–22.CrossRefPubMed
21.
Zurück zum Zitat Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10.CrossRefPubMed Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404–10.CrossRefPubMed
22.
Zurück zum Zitat Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther. 2017;35(1):10–8.CrossRefPubMed Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther. 2017;35(1):10–8.CrossRefPubMed
23.
Zurück zum Zitat Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60(18):1790–6.CrossRefPubMed Deftereos S, Giannopoulos G, Kossyvakis C, et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012;60(18):1790–6.CrossRefPubMed
Metadaten
Titel
Colchicine for the Prevention of Recurrent Arrhythmia After Catheter Ablation of Atrial Fibrillation: Results of a Single-Center, Retrospective Study
verfasst von
Kristen Bova Campbell
Stephanie Dougherty Eickman
Tracy Truong
Eric Black-Maier
Adam S. Barnett
Allen Wang
Cynthia L. Green
James P. Daubert
Robert K. Lewis
Brett D. Atwater
Sana M. Al-Khatib
Tristram D. Bahnson
Kevin L. Thomas
Kevin P. Jackson
Larry R. Jackson
Sean Pokorney
Camille Frazier-Mills
Jonathan P. Piccini
Publikationsdatum
06.10.2023
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 6/2023
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-023-00612-6

Weitere Artikel der Ausgabe 6/2023

American Journal of Cardiovascular Drugs 6/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.